193 related articles for article (PubMed ID: 30591038)
1. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
McKenzie KA; El Ters M; Torres VE; Harris PC; Chapman AB; Mrug M; Rahbari-Oskoui FF; Bae KT; Landsittel DP; Bennett WM; Yu ASL; Mahnken JD
BMC Nephrol; 2018 Dec; 19(1):378. PubMed ID: 30591038
[TBL] [Abstract][Full Text] [Related]
2. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
Nowak KL; Cadnapaphornchai MA; Chonchol MB; Schrier RW; Gitomer B
Am J Nephrol; 2016; 44(3):171-8. PubMed ID: 27548646
[TBL] [Abstract][Full Text] [Related]
4. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
[TBL] [Abstract][Full Text] [Related]
5. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
[TBL] [Abstract][Full Text] [Related]
6. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
7. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
[TBL] [Abstract][Full Text] [Related]
8. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
Boertien WE; Meijer E; Li J; Bost JE; Struck J; Flessner MF; Gansevoort RT; Torres VE;
Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
Girardat-Rotar L; Puhan MA; Braun J; Serra AL
J Nephrol; 2018 Feb; 31(1):87-94. PubMed ID: 28386880
[TBL] [Abstract][Full Text] [Related]
10. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
[TBL] [Abstract][Full Text] [Related]
12. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
13. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
[TBL] [Abstract][Full Text] [Related]
14. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
15. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.
Pejchinovski M; Siwy J; Metzger J; Dakna M; Mischak H; Klein J; Jankowski V; Bae KT; Chapman AB; Kistler AD
Nephrol Dial Transplant; 2017 Mar; 32(3):487-497. PubMed ID: 27382111
[TBL] [Abstract][Full Text] [Related]
16. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
Irazabal MV; Rangel LJ; Bergstralh EJ; Osborn SL; Harmon AJ; Sundsbak JL; Bae KT; Chapman AB; Grantham JJ; Mrug M; Hogan MC; El-Zoghby ZM; Harris PC; Erickson BJ; King BF; Torres VE;
J Am Soc Nephrol; 2015 Jan; 26(1):160-72. PubMed ID: 24904092
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.
Bais T; Geertsema P; Knol MGE; van Gastel MDA; de Haas RJ; Meijer E; Gansevoort RT;
Clin J Am Soc Nephrol; 2024 May; 19(5):591-601. PubMed ID: 38407866
[TBL] [Abstract][Full Text] [Related]
18. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
[TBL] [Abstract][Full Text] [Related]
19. Caffeine intake by patients with autosomal dominant polycystic kidney disease.
Vendramini LC; Nishiura JL; Baxmann AC; Heilberg IP
Braz J Med Biol Res; 2012 Sep; 45(9):834-40. PubMed ID: 22801417
[TBL] [Abstract][Full Text] [Related]
20. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.
Helal I; McFann K; Reed B; Yan XD; Schrier RW; Fick-Brosnahan GM
Nephrol Dial Transplant; 2013 Feb; 28(2):380-5. PubMed ID: 23222419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]